Literature DB >> 19431076

Age-related macular degeneration: an immunologically driven disease.

Robert B Nussenblatt1, Baoying Liu, Zhuqing Li.   

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in elderly individuals worldwide. Genome-wide association studies have provided evidence that the immune system is involved in the pathogenesis of AMD. This review discusses historical and more recent studies that have led to the recognition that AMD is an intraocular inflammatory disease, and that is possibly driven by an immune response. A particular focus of this review is recent studies on the contribution of the complement system and macrophages to the pathogenesis of AMD. A working hypothesis is also presented that may reconcile the current understanding of the pathogenesis of AMD and some apparently contradictory findings in the literature.

Entities:  

Mesh:

Year:  2009        PMID: 19431076

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  31 in total

1.  Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization.

Authors:  Juan Liu; Purushottam Jha; Valeriy V Lyzogubov; Ruslana G Tytarenko; Nalini S Bora; Puran S Bora
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

Review 2.  Vitamin D: Implications for ocular disease and therapeutic potential.

Authors:  Rose Y Reins; Alison M McDermott
Journal:  Exp Eye Res       Date:  2015-02-25       Impact factor: 3.467

3.  Human induced pluripotent stem-derived retinal pigment epithelium (RPE) cells exhibit ion transport, membrane potential, polarized vascular endothelial growth factor secretion, and gene expression pattern similar to native RPE.

Authors:  Maria Kokkinaki; Niaz Sahibzada; Nady Golestaneh
Journal:  Stem Cells       Date:  2011-05       Impact factor: 6.277

Review 4.  The role of epigenetics in age-related macular degeneration.

Authors:  M Gemenetzi; A J Lotery
Journal:  Eye (Lond)       Date:  2014-09-19       Impact factor: 3.775

Review 5.  Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.

Authors:  Steven Yeh; Thomas A Albini; Andrew A Moshfeghi; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2012-09       Impact factor: 5.258

6.  A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization.

Authors:  Robert B Nussenblatt; Gordon Byrnes; H Nida Sen; Steven Yeh; Lisa Faia; Catherine Meyerle; Keith Wroblewski; Zhuqing Li; Baoying Liu; Emily Chew; Patti R Sherry; Penelope Friedman; Fred Gill; Frederick Ferris
Journal:  Retina       Date:  2010 Nov-Dec       Impact factor: 4.256

7.  A new immunodeficient pigmented retinal degenerate rat strain to study transplantation of human cells without immunosuppression.

Authors:  Magdalene J Seiler; Robert B Aramant; Melissa K Jones; Dave L Ferguson; Elizabeth C Bryda; Hans S Keirstead
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-13       Impact factor: 3.117

8.  Pro-angiogenic effect of IFNgamma is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells.

Authors:  Baoying Liu; Lisa Faia; Mengjun Hu; Robert B Nussenblatt
Journal:  Mol Vis       Date:  2010-02-10       Impact factor: 2.367

9.  Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration.

Authors:  Monica Dalal; Naima Jacobs-El; Benjamin Nicholson; Jingsheng Tuo; Emily Chew; Chi-Chao Chan; Robert Nussenblatt; Frederick Ferris; Catherine Meyerle
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-21       Impact factor: 3.117

10.  γδ T cells as a major source of IL-17 production during age-dependent RPE degeneration.

Authors:  Zhenyang Zhao; Pei Xu; Zuliang Jie; Yiqin Zuo; Bo Yu; Lynn Soong; Jiaren Sun; Yan Chen; Jiyang Cai
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.